TCR² Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult for the Manufacturing of its Novel T Cell Therapies for Cancer
"The agreement with CGT Catapult enables us to meet our immediate clinical trials needs and have the flexibility of both our own dedicated manufacturing space and access to an established supply chain at one of the world's premier centers for cell and gene therapy development," said
The CGT Catapult manufacturing center was established to allow companies developing cell and gene therapies to manufacture at scale, to Good Manufacturing Practice (GMP) standards. The center, underpinned by support from CGT Catapult experts across scientific research, manufacturing, supply, and regulation, provides the required capabilities for manufacture at high throughput in GMP environment, in terms of raw materials supply, quality control testing, cryostorage, logistics, track and trace, and integration into the wider supply chain. In
"We are delighted to welcome TCR2 Therapeutics as the latest pioneering company to use the CGT Catapult manufacturing centre as its base for producing advanced therapies. It's fantastic that the appeal of our unique facilities – and the wider
TCR2 Therapeutics is the first U.S. company to establish manufacturing operations at the CGT Catapult manufacturing center in
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC™-T cells) specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex independent of human leukocyte antigen (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarincoma. For more information about TCR2, please visit www.tcr2.com.
About the Cell and Gene Therapy Catapult
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the
Forward-Looking Statements Disclaimer
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding TCR2's progress and timing of TCR2's manufacturing programs. Although TCR2's management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of TCR2, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in TCR2's operating plans that may impact its cash expenditures, the uncertainties inherent in research and development, process development, and manufacturing, as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by TCR2, including those risks and uncertainties listed in TCR2's most report on Form S-1 filed with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and TCR2 does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
View original content:http://www.prnewswire.com/news-releases/tcr2-therapeutics-announces-collaboration-with-cell-and-gene-therapy-catapult-for-the-manufacturing-of-its-novel-t-cell-therapies-for-cancer-300817433.html
For TCR2 Therapeutics: Kathy Vincent, (310) 403-8951, email@example.com; or For CGT Catapult: FTI Consulting: Michael Trace +44 (0) 203 319 5674 / firstname.lastname@example.org; or Andrew Ward + 44 (0) 203 727 1179 / email@example.com